These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17131338)

  • 1. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage.
    Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Kratz F; Walker UA
    Int J Cancer; 2007 Feb; 120(4):927-34. PubMed ID: 17131338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin.
    Lebrecht D; Kokkori A; Ketelsen UP; Setzer B; Walker UA
    J Pathol; 2005 Dec; 207(4):436-44. PubMed ID: 16278810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
    Kratz F; Ehling G; Kauffmann HM; Unger C
    Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
    Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
    Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
    Kratz F; Azab S; Zeisig R; Fichtner I; Warnecke A
    Int J Pharm; 2013 Jan; 441(1-2):499-506. PubMed ID: 23149257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials.
    Kratz F
    Expert Opin Investig Drugs; 2007 Jun; 16(6):855-66. PubMed ID: 17501697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of mtDNA lesions in anthracycline cardiotoxicity.
    Lebrecht D; Walker UA
    Cardiovasc Toxicol; 2007; 7(2):108-13. PubMed ID: 17652814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
    Unger C; Häring B; Medinger M; Drevs J; Steinbild S; Kratz F; Mross K
    Clin Cancer Res; 2007 Aug; 13(16):4858-66. PubMed ID: 17699865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy.
    Lebrecht D; Setzer B; Ketelsen UP; Haberstroh J; Walker UA
    Circulation; 2003 Nov; 108(19):2423-9. PubMed ID: 14568902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of the conjugate of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin with lactosaminated human albumin by 13C NMR spectroscopy.
    Boga C; Fiume L; Baglioni M; Bertucci C; Farina C; Kratz F; Manerba M; Naldi M; Di Stefano G
    Eur J Pharm Sci; 2009 Oct; 38(3):262-9. PubMed ID: 19695327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin Binding Domain Fusing R/K-X-X-R/K Sequence for Enhancing Tumor Delivery of Doxorubicin.
    Liu L; Zhang C; Li Z; Wang C; Bi J; Yin S; Wang Q; Yu R; Liu Y; Su Z
    Mol Pharm; 2017 Nov; 14(11):3739-3749. PubMed ID: 28950700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.
    Lebrecht D; Setzer B; Rohrbach R; Walker UA
    Nephrol Dial Transplant; 2004 Feb; 19(2):329-36. PubMed ID: 14736955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Drug Delivery Biopolymers Effectively Inhibit Breast Tumor Growth and Prevent Doxorubicin-Induced Cardiotoxicity.
    Dragojevic S; Ryu JS; Hall ME; Raucher D
    Molecules; 2022 May; 27(11):. PubMed ID: 35684309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice.
    Pillai VB; Bindu S; Sharp W; Fang YH; Kim G; Gupta M; Samant S; Gupta MP
    Am J Physiol Heart Circ Physiol; 2016 Apr; 310(8):H962-72. PubMed ID: 26873966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy.
    Lebrecht D; Kirschner J; Geist A; Haberstroh J; Walker UA
    Cardiovasc Pathol; 2010; 19(5):e167-74. PubMed ID: 19747854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered mitochondrial epigenetics associated with subchronic doxorubicin cardiotoxicity.
    Ferreira A; Cunha-Oliveira T; Simões RF; Carvalho FS; Burgeiro A; Nordgren K; Wallace KB; Oliveira PJ
    Toxicology; 2017 Sep; 390():63-73. PubMed ID: 28865727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity.
    Russo M; Guida F; Paparo L; Trinchese G; Aitoro R; Avagliano C; Fiordelisi A; Napolitano F; Mercurio V; Sala V; Li M; Sorriento D; Ciccarelli M; Ghigo A; Hirsch E; Bianco R; Iaccarino G; Abete P; Bonaduce D; Calignano A; Berni Canani R; Tocchetti CG
    Eur J Heart Fail; 2019 Apr; 21(4):519-528. PubMed ID: 30843309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart.
    Montaigne D; Marechal X; Baccouch R; Modine T; Preau S; Zannis K; Marchetti P; Lancel S; Neviere R
    Toxicol Appl Pharmacol; 2010 May; 244(3):300-7. PubMed ID: 20096298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate.
    Di Stefano G; Lanza M; Kratz F; Merina L; Fiume L
    Eur J Pharm Sci; 2004 Dec; 23(4-5):393-7. PubMed ID: 15567293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase.
    Octavia Y; Kararigas G; de Boer M; Chrifi I; Kietadisorn R; Swinnen M; Duimel H; Verheyen FK; Brandt MM; Fliegner D; Cheng C; Janssens S; Duncker DJ; Moens AL
    J Cell Mol Med; 2017 Dec; 21(12):3277-3287. PubMed ID: 28608983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.